-
MindMed Begins First-Ever Clinical Trial On MDMA, LSD Combinations
Wednesday, January 20, 2021 - 10:11am | 471Mind Medicine (MindMed) Inc (OTC: MMEDF), a medicine biotech company in psychedelics, on Wednesday announced its start of the first-ever clinical trial measuring and evaluating 3,4-methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) combinations in the human body, at the...
-
Why Supernus Shares Rallied 24% After-Hours On Tuesday
Wednesday, December 23, 2020 - 1:48am | 295Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline results in late-stage trials. What Happened Supernus claimed that the daily active...
-
Emerald Health Pharmaceuticals To Raise $17M Via New Reg A+ Round
Thursday, December 3, 2020 - 5:38pm | 323Emerald Health Pharmaceuticals Inc. (EHP) is launching a new financing round under its Regulation A offering. The round will open on Monday, Dec. 7, and expire on Mar. 28, 2021, or upon raising roughly $17 million, which is the maximum amount to be raised, the Sand Diego biotech company said....
-
Inovio Coronavirus Vaccine To Enter Mid-To-Late Stage Testing In September
Tuesday, August 11, 2020 - 12:00am | 478Inovio Pharmaceuticals Inc (NASDAQ: INO) said during the earnings call Monday it expected its COVID-19 vaccine to enter mid-to-late stage human trials in September, Reuters reported. Coronavirus Vaccine Update: The Pennsylvania-based drugmaker had previously estimated it would begin the phase...
-
Regeneron Says Its Coronavirus Antibody Cocktail Shows Promise For Both Prevention, Treatment In Animal Testing
Tuesday, August 4, 2020 - 12:32am | 475Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Monday that a non-peer-reviewed study indicated its antibody drug combination both prevented and treated COVID-19 in animals, as earlier reported by Reuters. What Happened The drugmaker noted a cocktail of two monoclonal antibodies...
-
Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development
Sunday, July 26, 2020 - 10:38pm | 445Moderna Inc. (NASDAQ: MRNA) announced Sunday it is receiving another $472 million funding from President Donald Trump's administration to support late-stage clinical development of its coronavirus vaccine candidate, including an expanded phase 3 study. What Happened The Cambridge...
-
Johnson & Johnson Says Late-Stage Coronavirus Vaccine Trials Moved Ahead To September
Friday, July 17, 2020 - 6:42am | 415Johnson & Johnson (NYSE: JNJ) said Thursday it would begin late-stage human trials for its COVID-19 vaccine ahead of schedule in September, with the phase one trials involving 1,000 people set to begin next week. What Happened The New Jersey-based company's Chief Scientific Officer, ...
-
Omeros Shares Fall Over 40% On Renal Disease Trial Results
Monday, October 1, 2018 - 4:37pm | 359Biopharma Omeros Corporation (NASDAQ: OMER) released additional data Monday from the company’s OMS721 clinical trial in renal disease. What Happened Omeros shares were down 42.81 percent at $13.96 at the close monday. The Phase 2 trial measured protein levels in the...